Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

60 Degrees Pharmaceuticals (SXTP) Change in Receivables (2022 - 2025)

60 Degrees Pharmaceuticals (SXTP) has disclosed Change in Receivables for 4 consecutive years, with $379002.0 as the latest value for Q3 2025.

  • On a quarterly basis, Change in Receivables rose 1280.6% to $379002.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $350214.0, a 88.48% increase, with the full-year FY2024 number at $255416.0, up 37.79% from a year prior.
  • Change in Receivables was $379002.0 for Q3 2025 at 60 Degrees Pharmaceuticals, up from -$193209.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $379002.0 in Q3 2025 to a low of -$193209.0 in Q2 2025.
  • A 4-year average of $47977.2 and a median of $36890.0 in 2023 define the central range for Change in Receivables.
  • Biggest YoY gain for Change in Receivables was 1280.6% in 2025; the steepest drop was 873.35% in 2025.
  • 60 Degrees Pharmaceuticals' Change in Receivables stood at -$149076.0 in 2022, then skyrocketed by 162.6% to $93323.0 in 2023, then soared by 74.58% to $162926.0 in 2024, then surged by 132.62% to $379002.0 in 2025.
  • Per Business Quant, the three most recent readings for SXTP's Change in Receivables are $379002.0 (Q3 2025), -$193209.0 (Q2 2025), and $1495.0 (Q1 2025).